Clovis Oncology

Update on Coronavirus (COVID-19)

See our latest statement here

You are about to download this document, please enter your contact details below to start downloading.

Case Studies

Clovis Oncology

Clovis Oncology has chosen Quotient’s drug product optimization approach for rociletinib, a promising oral candidate drug for the treatment of EGFR-resistant non-small cell lung cancer.

First name

Last name

Company name

Job title

City

Country

Your email

Phone number

Would you like to receive further scientific content including case studies, whitepapers and seminar and webinar invitations?

Yes, please keep me informed
No, please opt me out of further communications

You can find out how we handle your personal information in our privacy policy here.

Ask us a question

We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.